BBIO
BridgeBio Pharma, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Viking Global Investors | Q3 2019 | 28Q | $26 | $65 | +152% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $24 | $65 | +169% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $24 | $65 | +169% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $65 | — |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $24 | $65 | +169% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $65 | — |
| Renaissance Technologies re-entered | Q3 2025(8Q snapshot) | 3Q | $50 | $65 | +30% |
| Bridgewater Associates | Q1 2026 | 1Q | $75 | $65 | -13% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Duquesne Family Office | Q2 2025 | Q3 2025 | → $51 | +52% |
| Point72 Asset Management 3× in & out | Q2 2025 | Q3 2025 | → $51 | +52% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BridgeBio Pharma, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001470831-26-000523Jun 8, 2026
- Form 40001470831-26-000488May 26, 2026
- Form 40001470831-26-000473May 19, 2026
- Form 40001470831-26-000472May 19, 2026
- Form 40001470831-26-000471May 19, 2026
- Form 40001470831-26-000470May 19, 2026
- Form 40001470831-26-000423May 11, 2026
- Form 40001470831-26-000410May 4, 2026
- Form 40001470831-26-000361Apr 13, 2026
- Form 40001470831-26-000304Mar 20, 2026
- Form 40001470831-26-000302Mar 20, 2026
- Form 40001470831-26-000296Mar 19, 2026
- Form 40001470831-26-000275Mar 16, 2026
- Form 40001470831-26-000260Mar 12, 2026
- Form 40001470831-26-000252Mar 6, 2026
Fundamentals
XBRL · BridgeBio Pharma, Inc.Annual figures sourced directly from BridgeBio Pharma, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BridgeBio Pharma, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 27, 2026
- 8-KMaterial eventMay 13, 2026
- 8-KFORM 8-KMay 8, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 24, 2026
- 8-KMaterial eventMar 30, 2026
- 10-KAnnual reportFeb 24, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventJan 21, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportOct 29, 2025
- 8-KMaterial eventOct 29, 2025
- 8-KMaterial eventOct 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $0.00 | — | +0% |
| Millennium Management | Q2 2026 | open | $0.00 | — | +0% |
| Renaissance Technologies | Q2 2026 | open | $70 | $65 | -6% |
| Citadel Advisors | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q1 2026 | open | $76 | $65 | -14% |
| Bridgewater Associates | Q1 2026 | open | $75 | $63 | -16% |
| Citadel Advisors | Q3 2025 | Q2 2026 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | $50 | $76 | +51% |
| D.E. Shaw | Q2 2025 | open | $34 | $65 | +94% |
| Millennium Management | Q2 2025 | open | $0.00 | — | +0% |
| Duquesne Family Office | Q2 2025 | Q3 2025 | $34 | $51 | +52% |
| Point72 Asset Management | Q2 2025 | Q3 2025 | $34 | $51 | +52% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $24 | $66 | +174% |
| Two Sigma Investments | Q3 2024 | open | $24 | $65 | +169% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $24 | $35 | +44% |
| D.E. Shaw | Q3 2024 | Q1 2026 | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $24 | $65 | +169% |
| Millennium Management | Q3 2024 | Q4 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $24 | $65 | +169% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| Point72 Asset Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Viking Global Investors | Q3 2019 | open | $26 | $63 | +143% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.